Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Net Income towards Common Stockholders: 2010-2025

Historic Net Income towards Common Stockholders for Niagen Bioscience (NAGE) over the last 14 years, with Sep 2025 value amounting to $4.6 million.

  • Niagen Bioscience's Net Income towards Common Stockholders rose 143.77% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year increase of 1275.69%. This contributed to the annual value of $8.6 million for FY2024, which is 273.15% up from last year.
  • Latest data reveals that Niagen Bioscience reported Net Income towards Common Stockholders of $4.6 million as of Q3 2025, which was up 26.85% from $3.6 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Net Income towards Common Stockholders ranged from a high of $7.2 million in Q4 2024 and a low of -$8.9 million during Q3 2021.
  • Its 3-year average for Net Income towards Common Stockholders is $1.5 million, with a median of $114,000 in 2023.
  • In the last 5 years, Niagen Bioscience's Net Income towards Common Stockholders plummeted by 110.11% in 2021 and then spiked by 24,160.00% in 2025.
  • Niagen Bioscience's Net Income towards Common Stockholders (Quarterly) stood at -$5.3 million in 2021, then soared by 72.88% to -$1.4 million in 2022, then soared by 107.89% to $114,000 in 2023, then skyrocketed by 6,197.37% to $7.2 million in 2024, then surged by 143.77% to $4.6 million in 2025.
  • Its last three reported values are $4.6 million in Q3 2025, $3.6 million for Q2 2025, and $5.1 million during Q1 2025.